« Return to News | CROs/Service Providers

Kendle’s Q3 Revenues Up 25%

Wednesday, November 5, 2008 01:02 PM

Cincinnati-based contract research organization (CRO) Kendle reported third quarter net service revenues of $124.8 million, an increase of 25% compared with the same period last year. Approximately 6% of the CRO’s revenue growth resulted from the June acquisition of DecisionLine, a Toronto-based phase I company focused on the central nervous system (CNS).

New business awards for the quarter totaled a record $212 million, an increase of 21% compared with the same period 2007. Kendle reduced the low end of its full-year revenue guidance just slightly to $485 million from $490 million. The high-end guidance remains at $500 million.

The CRO’s share prices were up 20% to $25.68 in morning trading.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.